Antigenic peptide vaccination: Provoking immune response and clinical benefit for cancer

Current Immunology Reviews

Volumn 4, Issue 4, 2008, Pages 235-241

  Tsukahara, Tomohide ^a   Torigoe, Toshihiko ^a   Tamura, Yasuaki ^a   Wada, Takuro ^a   Kawaguchi, Satoshi ^a   Tsuruma, Tetsuhiro ^a   Hirata, Koichi ^a   Yamashita, Toshihiko ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical trial; CTL epitope; Peptide vaccination; Tumor associated antigen

Indexed keywords

ALPHA INTERFERON; ANTIGENIC PEPTIDE VACCINE; ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CANCER VACCINE; DENILEUKIN DIFTITOX; FOLATE RECEPTOR 4 ANTIBODY; HEAT SHOCK PROTEIN 90; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIBODY; METHOTREXATE; OSTEOSARCOMA ANTIGEN PAPILLOMAVIRUS BINDING FACTOR; PAPILLOMAVIRUS BINDING FACTOR CYTOTOXIC T LYMPHOCYTE ANTIBODY; PAPILLOMAVIRUS BINDING FACTOR DERIVED PEPTIDE VACCINE; PEPTIDE VACCINE; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALPROIC ACID;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MELANOMA; NEOPLASM; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

EID: 63849303727     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339508786447959     Document Type: Review

References (82)

1. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5: 681-9.
2. van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 35: 9008-21.
3. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
4. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol 2007; 34: 524-31.
5. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
6. Van der Bruggen P, Traversari C, Chomez P, 0. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
7. Kawaguchi S, Wada T, Tsukahara T, et al. A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med 2005; 3: 31.
8. Van der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
9. Kawakami Y, Fujita T, Matsuzaki Y, et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004; 95: 784-91.
10. Tsukahara T, Kawaguchi S, Nagoya S, et al. Novel approach to immunotherapy for epithelial cancers, bone and soft-tissue sarcomas. Ann Cancer Res Ther 2004; 12: 53-70.
11. Sahara H, Nabeta Y, Torigoe T, et al. A gene encoding human gastric signet ring cell carcinoma antigen recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunother 2002; 25: 235-42.
12. Tsukahara T, Nabeta Y, Kawaguchi S, et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004; 64: 5442-8.
13. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 2008; 99: 368-75.
14. Tsukahara T, Kawaguchi S, Torigoe T, et al. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor, submitted 2008.
15. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
16. Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005; 11: 1000-9.
17. Maeda A, Ohguro H, Nabeta Y, et al. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol 2001; 31: 563-72.
18. Sato Y, Nabeta Y, Tsukahara T, et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002; 169: 1611-8.
19. Ida K, Kawaguchi S, Sato Y, et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004; 173: 1436-43.
20. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996; 88: 1635-44.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
22. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
23. Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Cancer vaccines: pessimism in check. Nat Med 2004; 10: 1278-9; author reply 9-80.
24. Manjili MH, Kmieciak M, Keeler J. Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma". J Immunol 2006; 176: 4511; author reply - 2.
25. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
26. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57.
27. Paulos CM, Kaiser A, Wrzesinski C, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13: 5280-9.
28. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117: 2197-204.
29. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
30. Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. Lancet Oncol 2005; 6: 3-4.
31. Khong HT, Yang JC, Topalian SL, et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004; 27: 472-7.
32. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007; 110: 203-14.
33. Roberts JD, Niedzwiecki D, Carson WE, et al. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 2006; 29: 95-101.
34. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007; 25: 2727-34.
35. Mavroudis D, Bolonakis I, Cornet S, et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006; 70: 306-14.
36. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-90.
37. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
38. Tsuruma T, Iwayama Y, Ohmura T, et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24.
39. Kawaguchi S, Wada T, Ida K, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
40. Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12: 1768-75.
41. Suekane S, Nishitani M, Noguchi M, et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 2007; 98: 1965-8.
42. Noguchi M, Itoh K, Yao A, et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 1-12.
43. Sato Y, Maeda Y, Shomura H, et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90: 1334-42.
44. Noguchi M, Itoh K, Suekane S, et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004; 95: 77-84.
45. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clin Cancer Res 2008; 14: 2740-8.
46. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803.
47. Slingluff CL, Jr., Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13: 6386-95.
48. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007; 25 (Suppl 2): B61-71.
49. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008; 105: 1650-5.
50. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.
51. Speiser DE, Baumgaertner P, Barbey C, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006; 177: 1338-48.
52. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87.
53. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-33.
54. Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother 2008; 31: 431-9.
55. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; 27: 145-59.
56. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68: 2561-3.
57. Teague RM, Greenberg PD, Fowler C, et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 2008; 28: 662-74.
58. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28: 698-709.
59. Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001; 98: 10290-5.
60. Karanikas V, Lurquin C, Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171: 4898-904.
61. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201: 241-8.
62. So T, Hanagiri T, Chapiro J, et al. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 2007; 56: 259-69.
63. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol 2005; 17: 320-5.
64. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
65. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
66. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-10.
67. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 2004; 25: 487-91.
68. Kitamura H, Torigoe T, Honma I, et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 2006; 12: 4641-4.
69. Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; 98: 1424-30.
70. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by antipan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-80.
71. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-32.
72. Campbell CJ, Cohen J, Enneking WF. Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg Am 1975; 57: 143-4.
73. Marcove RC. A clinical trial of autogenous vaccines in the treatment of osteogenic sarcoma. Beitr Pathol 1974; 153: 65-72.
74. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-77.
75. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-52.
76. Nabeta Y, Kawaguchi S, Sahara H, et al. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 2003; 8: 554-9.
77. Sichtig N, Silling S, Steger G. Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14-3-3beta. Arch Biochem Biophys 2007; 464: 90-9.
78. Ogihara Y, Takeda K, Yanagawa T, Hirasawa Y. Spontaneous regression of lung metastases from osteosarcoma. Cancer 1994; 74: 2798-803.
79. Bacci G, Palmerini E, Staals EL, et al. Spontaneous regression of lung metastasis from osteosarcoma: a case report. J Pediatr Hematol Oncol 2008; 30: 90-2.
80. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-20.
81. Kurotaki T, Tamura Y, Ueda G, et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol 2007; 179: 1803-13.
82. Tsan MF, Gao B. Heat shock protein and innate immunity. Cell Mol Immunol 2004; 1: 274-9.